A Phase I Study of Pegylated Liposomal Doxorubicin and Irinotecan in Patients with Solid Tumors

Publisher： Karger

E-ISSN： 1421-9794|55|6|441-445

ISSN： 0009-3157

Source： Chemotherapy, Vol.55, Iss.6, 2009-12, pp. : 441-445

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Phase I Study of Weekly Irinotecan Combined with Weekly Cisplatin in Patients with Advanced Solid Tumors

By  

Chemotherapy, Vol. 48, Iss. 4, 2002-09 ,pp. : 205-210

Karger

Access to resources Recommend Favorite

High Cumulative Doses of Pegylated Liposomal Doxorubicin Are Not Associated with Cardiac Toxicity in Patients with Gynecologic Malignancies

By  

Chemotherapy, Vol. 56, Iss. 2, 2010-04 ,pp. : 108-111

Karger

Access to resources Recommend Favorite

Hepatic Arterial Infusion with Irinotecan in Patients with Liver Metastases of Colorectal Cancer: Results of an Extended Phase I Study

By  

Chemotherapy, Vol. 59, Iss. 1, 2013-07 ,pp. : 66-73

Karger

Access to resources Recommend Favorite

Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience

By  

Chemotherapy, Vol. 61, Iss. 3, 2016-01 ,pp. : 122-126

Karger

Access to resources Recommend Favorite

A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma

By Verschraegen Claire F.   Movva Sujana   Ji Yongli   Schmit Berndt   Quinn Robert H.   Liem Ben   Bocklage Therese   Shaheen Monte  

Cancers, Vol. 5, Iss. 2, 2013-04 ,pp. : 418-429

MDPI

Access to resources Recommend Favorite